ACADIA Pharmaceuticals (ACAD) Earnings Date, Estimates & Call Transcripts $16.27 +0.06 (+0.37%) (As of 11/20/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ACADIA Pharmaceuticals Latest Earnings SummaryUpcoming Q4 Earnings DateFeb. 25EstimatedActual EPS (Nov. 6) $0.20 Beat By $0.06 Consensus EPS (Nov. 6) $0.14 ACADIA Pharmaceuticals released Q3 2024 earnings on November 6, 2024, reporting an EPS of $0.20, which topped analysts' consensus estimates of $0.14 by $0.06. Quarterly revenue rose 18.3% year-over-year to $250.40 million, above analyst estimates of $248.83 million. With a trailing EPS of $0.78 and a P/E Ratio of 20.86, ACADIA Pharmaceuticals' earnings are expected to grow 15.28% next year, from $0.72 to $0.83 per share. Conference Call AudioEarnings Press ReleaseEarnings Slide DeckACAD Upcoming EarningsACADIA Pharmaceuticals' next earnings date is estimated for Tuesday, February 25, 2025, based off prior year's reporting schedules. Get ACADIA Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ACADIA Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataACAD Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ACAD Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here ACADIA Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.01$0.12$0.06Q2 20243$0.09$0.16$0.13Q3 20243$0.08$0.22$0.17Q4 20243$0.10$0.14$0.12FY 202411$0.26$0.64$0.47Q1 20251$0.19$0.19$0.19Q2 20251$0.20$0.20$0.20Q3 20251$0.19$0.19$0.19Q4 20251$0.20$0.20$0.20FY 20254$0.78$0.78$0.78Q1 20261$0.22$0.22$0.22Q2 20261$0.33$0.33$0.33Q3 20261$0.32$0.32$0.32 ACADIA Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/25/2025(Estimated)------- 11/6/2024Q3 2024$0.14$0.20+$0.06$0.20$248.83M$250.40M 8/6/2024Q2 2024$0.18$0.20+$0.02$0.20$235.95M$241.96M 5/8/2024Q1 2024$0.04$0.10+$0.06$0.10$208.31M$205.83M 2/27/2024Q4 2023$0.32$0.28 -$0.04$0.28$223.79M$231.04M 11/2/2023Q3 2023-$0.43-$0.40+$0.03-$0.40$194.40M$211.70M8/2/2023Q2 2023-$0.12$0.01+$0.13$0.01$163.86M$165.20M Get the Latest News and Ratings for ACAD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 5/8/2023Q1 2023-$0.21-$0.27 -$0.06-$0.27$120.29M$118.46M 2/27/2023Q4 2022-$0.25-$0.26 -$0.01-$0.26$135.18M$136.49M ACADIA Pharmaceuticals Earnings - Frequently Asked Questions When is ACADIA Pharmaceuticals's earnings date? ACADIA Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates. Learn more on ACAD's earnings history. What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings? ACADIA Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, November, 6th. The company issued revenue guidance of $940.0 million-$960.0 million, compared to the consensus revenue estimate of $952.5 million. Did ACADIA Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, ACADIA Pharmaceuticals (NASDAQ:ACAD) reported $0.20 earnings per share (EPS) to beat the analysts' consensus estimate of $0.14 by $0.06. Learn more on analysts' earnings estimate vs. ACAD's actual earnings. How can I listen to ACADIA Pharmaceuticals's earnings conference call? The conference call for ACADIA Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How much revenue does ACADIA Pharmaceuticals generate each year? ACADIA Pharmaceuticals (NASDAQ:ACAD) has a recorded annual revenue of $726.44 million. How much profit does ACADIA Pharmaceuticals generate each year? ACADIA Pharmaceuticals (NASDAQ:ACAD) has a recorded net income of -$61.29 million. ACAD has generated $0.78 earnings per share over the last four quarters. What is ACADIA Pharmaceuticals's price-to-earnings ratio? ACADIA Pharmaceuticals (NASDAQ:ACAD) has a trailing price-to-earnings ratio of 20.86 and a forward price-to-earnings ratio of 22.60. What is ACADIA Pharmaceuticals's EPS forecast for next year? ACADIA Pharmaceuticals's earnings are expected to grow from $0.72 per share to $0.83 per share in the next year, which is a 15.28% increase. ` More Earnings Resources from MarketBeat Related Companies Arrowhead Pharmaceuticals Earnings Date Ionis Pharmaceuticals Earnings Date Jazz Pharmaceuticals Earnings Date Catalent Earnings Date Sarepta Therapeutics Earnings Date Revolution Medicines Earnings Date Qiagen Earnings Date Intra-Cellular Therapies Earnings Date Roivant Sciences Earnings Date Ascendis Pharma A/S Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here This page (NASDAQ:ACAD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACAD Stock Alerts